Purpose: In this study, to optimize the polymeric drug delivery system for cancer chemotherapy, we developed a new pH-sensitive polymeric carrier, poly(vinylpyrrolidoneco-dimethylmaleic anhydride) [PVD], that could gradually release native form of drugs with full activity, from the conjugates in response to changes in pH. We examined the usefulness of PVD as a polymeric drug carrier.
INTRODUCTION
The major limitation of antitumor agents, typified by Adriamycin (ADR, doxorubicin), used in clinical applications, is its severe toxicity, such as bone marrow suppression and cardiotoxicity (1) (2) (3) (4) . This is caused by the high and frequent dose of antitumor agents, which have a very short half-life and a wide tissue distribution. The chemical conjugation of antitumor agents with water-soluble polymeric carriers has been found recently to overcome these drawbacks. The conjugation of low molecular weight antitumor agents to water-soluble polymeric carriers, such as N-(2-hydroxypropyl)methylacrylamide, divinylether-co-maleic anhydride, styrene-co-maleic anhydride, dextran, and polyethylene glycol (PEG), offers a potential mechanism to improve cancer chemotherapy (5) (6) (7) (8) (9) (10) . Distribution of the conjugates, which have a higher molecular weight, is usually restricted to the intravascular space after i.v. injection due to the low permeability in most organs with a continuous capillary bed. In contrast, these macromolecular conjugates preferentially accumulate in solid tumors due to the enhanced permeability and retention effect (11, 12) . As a result, the polymeric drug delivery system (DDS) may selectively expand the therapeutic windows of antitumor agents.
However, there is a restriction on the clinical application of this polymeric DDS for cancer chemotherapy. For instance, after the ADR that is taken up into the tumor cells intercalates between double strands of DNA, its antitumor activity is induced by inhibition of DNA replication and topoisomerase activity in the tumor cells (13) . However, the intercalation of polymer-conjugated ADR between double strands of DNA is based on macromolecular interactions, which are sterically hindered by the attached polymeric carrier. The introduction of polymeric carriers to antitumor agents, including ADR, is generally targeted at ionic functional groups in the antitumor agent, some of which may play an important role for their cytotoxic activity. Additionally, the conjugates with larger molecular size are hardly taken up into tumor cells through various transporters, because these transporters carry low molecular weight antitumor agents. Thus, for obtaining in vivo antitumor effects, a sufficient amount of antitumor agents is required to be released from the conjugates, because polymer-conjugated anticancer drugs themselves seldom show antitumor activity. However, in most cases, the conjugate between an antitumor agent and a polymeric carrier is formed through stable covalent bonding. As a result, the antitumor therapeutic effects of these conjugates have often not been observed in their clinical trials. To overcome these problems, a relatively unstable linker was used for the conjugation between an antitumor agent and a polymeric carrier. Most of the antitumor agents released from the conjugates have a linker fragment. Furthermore, these modified antitumor agents show much lower specific activities than original antitumor agents in their native form, because the linker fragment is attached to an active functional group of the antitumor agents (14, 15) . Thus, it is necessary to develop a novel polymeric DDS for optimization of cancer chemotherapy.
Dimethylmaleic anhydride (DMMAn) with a double bond in its structure is used as a pH-reversible protective reagent of amino groups in proteins and chemical compounds (16, 17) . DMMAn binds to an amino group by forming an amide bond through its acid anhydride group over pH 8, and then reversibly dissociates from the amino group for change in pH to near slightly acidic from neutral. Thus, if a polymeric carrier with this function of DMMAn is synthesized, it will release a native drug in response to changes in pH. It is known that pH of both tumor and inflammatory tissues are slightly acidic unlike normal tissues (18) . Thus, the conjugates between an antitumor agent and the polymeric modifier with the function of DMMAn may show superior plasma half-life and tumor accumulation compared with unconjugated antitumor agents and, therefore, effectively release the antitumor agents in native form in the tumor tissues.
In this study, to optimize the polymeric DDS for cancer chemotherapy, poly(vinylpyrrolidone-co-dimethylmaleic anhydride) [PVD] was radically synthesized with vinylpyrrolidone and DMMAn. ADR was used as a model antitumor agent and conjugated with PVD along with other drugs. Fully active drugs were gradually released from the conjugates in response to the change in pH. The PVD-conjugated ADR showed superior antitumor activity against S-180 sarcomas in mice and had less side effects than free ADR. These results indicate that PVD is an effective polymeric carrier for cancer therapy.
MATERIALS AND METHODS
Materials. DMMAn was purchased from AKROS (Aichi, Japan). Other reagents and solvents were obtained from standard sources.
Synthesis of PVD. PVD was synthesized by the radical polymerization method using 4,4Ј-azobis-4-cyanovaleric acid as a radical initiator. Briefly, DMMAn and vinylpyrrolidone were mixed in a ratio of 1:20 in a glass tube containing dimethyl formamide and incubated at 60°C for 6 h. The resulting copolymer was precipitated in dry diethyl ether, collected immediately after filtration, and dried under vacuum three times. The molecular weight was determined by gel-filtration chromatography (GFC; TSKgel G4000PW, TSKgel ␣-3000 columns; Tosoh, Tokyo, Japan). Polyvinylpyrrolidone (PVP) was also similarly synthesized. These polymers were separated into several fractions by GFC to obtain polymers with a narrow molecular weight distribution.
Conjugation of Lucifer Yellow Cadaverine (LYC) with PVD. An amino group of water-soluble fluorophore LYC (1.27 mg/300 l of borate buffer; pH 8.5) was conjugated with PVD (6 mg) by forming an amide bond through its acid anhydride group. After the conjugation reaction for 30 min, the unconjugated free LYC was removed using 10-PG columns (Bio-Rad, Hercules, CA). PVD-modified LYC (PVD-LYC) was separated and purified by GFC. The release of free LYC from the PVD-LYC was not observed at pH 8.5. The solution of PVD-LYC was prepared to desired pH values and incubated at 37°C. Samples collected after various incubation times, went through desalting columns, and were analyzed for ratios between conjugated LYC and free LYC by measuring fluorescence intensity at 530 nm (emission) with excitation at 424 nm. The release of LYC from the conjugate in the serum was also measured by the same method after mixing it with an equal volume of mouse serum.
Toxicity of PVD. Monkey renal tubular (LLC-MK2) cells were seeded in 96-well plates at a concentration of 1.2 ϫ 10 4 cells/well. After incubation for 24 h at 37°C, LLC-MK2 cells were incubated with PVD, PVP, PEG, and Polybrene at different concentrations. The plates were incubated for 24 h at 37°C, and cell viability was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Dojindo, Kumamoto, Japan) assay as described by Mosmann (19) with minor modifications. Briefly, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (5 mg/ml; 10 l) was added into each well, and the cells were incubated at 37°C for 4 h. The resulting formazan product was dissolved by the addition of 100 l of 10% SDS (Wako Pure Chemical Ind. Co., Ltd., Osaka, Japan) and 15 mM HCl. The solution was read on a microplate reader at 595 nm test wavelength with a reference wavelength of 655 nm.
Pharmacokinetic Analysis. PVD and PVP were dissolved in dimethyl formamide and activated for 24 h at room temperature with dicyclohexyl carbodiimide and N-hydroxysuccinimide, respectively. The polymers were incubated with thyramine hydrochloride for 24 h at 4°C, dialyzed in water, and lyophilized. Polymer-thyramine conjugates were radiolabeled by the chloramine-T method.
125 I-labeled polymer was purified by GFC. The clearance profiles of PVD and PVP (10 g/mouse; 1 ϫ 10 6 cpm/200 l in saline) were studied after i.v. injection into the tail veins of ddY mice. Blood was collected from the tail vein at intervals, and radioactivity was measured. GFC analysis confirmed that Ͼ95% of the radioactivity in circulating blood 3 h after i.v. injection was derived from intact 125 I-PVD and 125 I-PVP. Mice were housed in metabolic cages to collect urine and sacrificed 3 h after treatment to evaluate tissue distribution.
Conjugation of ADR with PVD. PVD was dissolved in N-methyl-2-pyrrolidone at a concentration of 80 mg/4 ml. Then ADR (20 mg) was added to this solution. After the addition of triethylaminde (30 ml), the mixture was additionally incubated overnight at room temperature. After the reaction, distilled water was added, and pH of the mixture was adjusted to 8.5 by the addition of 0.2 M NaH 2 PO 4 . Unconjugated ADR was removed by ultrafiltration using a PM-30 (Amicon). The PVDmodified ADR (PVD-ADR) was then purified by dialysis. The amount of conjugated ADR was estimated by measuring its absorbance at 340 nm.
In Vivo Antitumor Activity of PVD-ADR. In vivo antitumor effects of PVD-ADR were assessed by using ddY mice bearing mouse sarcoma-180 solid tumors. PVD-ADR and free ADR were injected i.v. to the mice at different doses, 60, 200, and 600 g/mouse (ADR-equivalent dose) on days 7, 9, and 11 after tumor inoculation. The tumor volume was measured by a standard method as described elsewhere (20, 21) .
RESULTS
Chemical Structure of PVD. For the radical synthesis of PVD, DMMAn was introduced at a ratio of 5% to the amount of vinylpyrrolidone. The average molecular weight of PVD was M r 6,000 [Polydispersity (molecular weight/the number average molecular weight) ϭ 1.14]. PVD was synthesized by radical copolymerization. Reflecting the properties of DMMAn, drugs were conjugated with PVD by forming an amide bond through its acid anhydride group of DMMAn to amino groups of drugs at more than pH 8.0 and released at lower than pH 7.0 (Fig. 1) .
The pH-Sensitive Drug (LYC) Release from PVD-Conjugated LYC. The release of LYC as a model drug, which is a fluorophore with an amino group, from PVD-LYC was assessed. The release of LYC from PVD-LYC was time dependent, and the release speed increased with an increase in the pH (Fig. 2) . At pH 8.5, a weak basic condition, almost no release or Ͻ1% release of LYC was observed. However, ϳ6% of the total LYC was released at pH 6.0 after 24 h incubation. Additionally, ϳ3% of the LYC was gradually released at pH 7.0 after 24 h of incubation. When PVD-LYC was incubated in the serum, results similar to the LYC release pattern at pH 6.0 were obtained.
Cytotoxicity of PVD. The in vitro cytotoxicity of PVD was assessed for clarifying its usefulness as a polymeric drug carrier. PVP and PEG had no effect on LLC-MK2 cells, whereas the cationic polymer, Polybrene, which is known to be an antitumorigenic agent, showed considerable cytotoxicity (Fig.  3) . In contrast, PVD was not cytotoxic at concentrations up to 3 mg/ml. Evidently, PVD as well as PVP and PEG had no cytotoxic effect on human endothelial cells (data not shown).
Pharmacokinetics of PVD after i.v. Administration. The pharmacokinetics of PVD and PVP after i.v. administration were studied for 3 h (Fig. 4) . PVP was separated and purified by GFC to adjust the molecular weight and polydispersity of PVD. PVD was effectively retained in blood as compared with PVP, although PVP was found previously to have the longest plasma half-life and to be the most suitable polymeric drug carrier for localizing the conjugated drug in blood. The half-lives of PVD and PVP were ϳ10 min and 30 min, respectively.
In Vivo Antitumor Effect of PVD-ADR.
To clarify the usefulness of PVD as a polymeric drug carrier for optimization of cancer chemotherapy, we synthesized PVD-ADR and compared its antitumor potency with that of ADR alone ( Fig. 5 and  6 , Table 1 ). Through GFC analysis, we confirmed that PVD-ADR was composed of one PVD molecule and one ADR molecule. As shown in Fig. 6 , all of the mice administered with free ADR at a dose of 600 g/mouse and 200 g/mouse died ϭ 3) ; bars, Ϯ SD. OE, polyethylene glycol; ‚, polyvinylpyrrolidone; F, Polybrene; E, poly(vinylpyrrolidone-co-dimethylmaleic anhydride). within 6 -10 days after their i.v. administration (within 13 days or 17 days after tumor inoculation) because of toxicity of ADR. There was a marked weight loss in these mice after the high dose of free ADR (data not shown). In mice treated with free ADR at a dose of 60 g/mouse, although tumor growth was slightly inhibited without causing sudden death or weight loss (Figs. 5 and 6 ), complete tumor regression, defined as disappearance of tumor without regrowth within 100 days, was not observed (Table 1) . Similar results were also observed in mice administered with a mixture of PVD and free ADR due to side effects (data not shown). In contrast, the antitumor activity of PVD-ADR at a dose of 60 g ADR/mouse was more effective than that of free ADR at 60 g/mouse (Fig. 5) . Tumor growth was remarkably and completely inhibited by PVD-ADR at a dose of 200 g ADR/mouse and 600 g ADR/mouse (Fig. 5) . Complete tumor regression was observed in 75%, 25%, and 25% of mice treated with PVD-ADR at a dose of 600 g ADR/mouse, 200 g ADR/mouse, and 60 g ADR/mouse, respectively (Table 1) . During the experimental period, all doses of PVD-ADR were well tolerated, and no loss in body weight was observed (Fig. 6) . 125 I-labeled PVP and 125 I-labeled PVD were i.v. administered to normal ddY mice, and the radioactivity in blood was measured. The curved line was drawn by using the least-squares method based on measured values at indicated time intervals. Mice were used in groups of 4. Each value is mean; bars, Ϯ SE. E, PVP; F, PVD. The ADR and PVD-ADR were i.v. administered to sarcoma-180 solid tumor-bearing mice on days 7, 9, and 11, after tumor inoculation. Data were expressed as relative tumor volume by the following equation: Relative tumor volume ϭ mean tumor volume at a given time/mean tumor volume on day 7. Mice were used in groups of 4. Each value is mean; bars, Ϯ SE. Intact mice, ࡗ. Open symbol, free ADR-treated mice. E, 600 g/mouse/day; ‚, 200 g/mouse/day; Ⅺ, 60 g/mouse/day. Closed symbol, PVD-ADR-treated mice. F, 600 g/ mouse/day; OE, 200 g/mouse/day; f, 60 g/mouse/day. Fig. 6 Survival time of the sarcoma-180 tumor-bearing mice treated with Adriamycin (ADR) and poly(vinylpyrrolidone-co-dimethylmaleic anhydride) [PVD]-ADR. The ADR and PVD-ADR were i.v. administered to sarcoma-180 solid tumor-bearing mice on days 7, 9, and 11, after tumor inoculation. Mice were used in groups of 4. Survival time of treated-mice after i.v. administration of ADR and PVD-ADR were shown as the survival rate (%). Open symbol, free ADR. E, 600 g/mouse/day; ‚, 200 g/mouse/day; Ⅺ, 60 g/mouse/day. Closed symbol, PVD-ADR. F, 600 g/mouse/day; OE, 200 g/mouse/day; f, 60 g/mouse/day.
DISCUSSION
In this study, to optimize the polymeric DDS for cancer chemotherapy, we attempted to develop a novel polymeric carrier that could release a native form of drugs in response to changes in pH near the neutrality. As described in the "Introduction," there are certain characteristics needed by the polymeric drug carrier: (a) to be excellent in blood residency for effectively obtaining the enhanced permeability and retention effect in tumors; (b) to gradually release the fully active form (native form) of antitumor agents; and (c) to efficiently release the native antitumor agents under the slightly acidic conditions, if possible, because it is known that the pH of tumor tissues is slightly lower than that of normal tissues (18) . From such a viewpoint, some polymeric carriers, typified by divinylether-comaleic anhydride and styrene-co-maleic anhydride, were developed (6, 7) . Some maleic anhydride, that is one of the acid anhydride, were contained in the structure of these polymeric carriers, and the antitumor agents were conjugated with these polymeric carriers via the formation of amide bonds between the amino group of antitumor agents and the acid anhydride groups. However, the amide bonds formed through maleic anhydride are very stable near neutral pH, and the antitumor agents are released from the conjugates under strong acidic conditions (ϽpH 3). As a result, the antitumor therapeutic effects of these conjugates have often not been observed in their clinical trials. In contrast, DMMAn binds to an amino group by forming an amide bond through its acid anhydride group over pH 8, and then reversibly dissociates from the amino group on change in pH to slightly acidic from neutral. However, there are no reports about DMMAn-introduced carrier.
For enhancing the blood residency of drugs, PVP was found to be one of the most useful polymeric carriers, because the plasma half-life of PVP itself was much longer than those of PEG and other polymeric modifiers (21, 22) . In fact, PVPconjugated tumor necrosis factor (TNF)-␣ showed a higher half-life than PEG-conjugated TNF-␣ despite having the same molecular size (21) . As a result, PVP-conjugated TNF-␣ had a more potent antitumor effect than PEG-conjugated TNF-␣, without any toxic side effects. This phenomenon has also been observed in PVP-conjugated interleukin 6 and leukemia inhibitory factor (22) . Furthermore, PVP can be introduced in various useful functional groups by radical copolymerization (23) . Additionally, the safety of PVP has been clinically confirmed. Using PVP as a backbone polymer, we synthesized PVD as a novel polymeric carrier for the development of antitumor polymeric DDS. Reflecting the property of DMMAn, the conjugate between PVD and drugs (LYC) could gradually release the native drugs directly (nonlinker) by responding to a change in pH near neutrality (Fig. 2) . As shown in Fig. 3 , the safety of PVD appears to be similar to PEG and PVP, which are used clinically. Additionally, the plasma half-life of PVD was longer than that of parental PVP (Fig. 4) . These results strongly suggested that PVD may be useful as a polymeric drug carrier for cancer chemotherapy.
We show here that the conjugation of ADR with PVD increases its antitumor activity while decreasing its nonspecific toxicity ( Figs. 5 and 6 ; Table 1 ). Overall, the therapeutic window is markedly increased. These results have important clinical implications for the use of antitumor chemotherapeutic agents in patients. The expansion of the therapeutic window is probably due to the following reasons. It is known that vascular permeability of macromolecules into solid tumors and its retention in tumor tissues are enhanced compared with normal tissues. This is generally called the enhanced permeability and retention effect (11, 12) . Thus, this enhanced permeability and retention effect may effectively accumulate the PVD-ADR in tumors. Additionally, as it is known that pH of tumor tissues is slightly lower than that of normal tissues, the PVD-ADR is likely to release free ADR more efficiently in tumor tissues (18) . But detailed studies on the pharmacokinetics of PVD-ADR are necessary to clarify the mechanism of its wider therapeutic window, and these are currently under investigation.
To improve the therapeutic bioavailability of bioactive proteins, bioactive proteins have been conjugated with watersoluble polymers such as PEG (24) . PEGylation of proteins increases their molecular size and enhances steric hindrance, both of which are dependent on PEG attached to the protein. This results in the improvement of the plasma half-lives of proteins and stability against proteolytic cleavage as well as a decrease in its immunogenicity. We also reported that PEGylation of proteins, such as TNF-␣, interleukin 6, and immunotoxin, could enhance therapeutic potency and could reduce undesirable side effects (21) (22) (23) (25) (26) (27) . However, there is a restriction to this approach, because PEGylation is frequently accompanied with a significant loss of specific activity of a protein. Lysine amino groups of proteins are often used for PEGylation because they are highly reactive. This PEGylation, however, is nonspecific and occurs at the NH 2 terminus as well as at all of the internal lysine residues in proteins, some of which may be in or near their active site. Resultant PEGylated proteins are heterogeneous and show significantly lower bioactivity. These problems remarkably limit the clinical application of PEGylated proteins. The present study shows that PVD effectively releases fully active drugs in the native form at neutral pH ranges and is a safe drug carrier that has no cytotoxicity. Additionally, PVD may be a suitable polymeric carrier for the prolongation of plasma half-life of drugs as well as PVP, rather than PEG. Thus, we are now attempting to design the PVDconjugated cytokines for promotion of protein therapies against solid and metastatic tumors.
In conclusion, we developed a new polymeric carrier, PVD, that could gradually release native drugs from the conjugate in response to changes in pH near neutrality. The PVD-ADR showed superior antitumor activity and had less side effects than free ADR. This enhancement of the antitumor therapeutic window may be due to not only the improvement of plasma half-lives and tumor accumulation of ADR, but also its controlled and sustained release from the conjugates in vivo. These results indicate that PVD is an effective polymeric carrier for cancer therapy.
